268 filings
Page 2 of 14
8-K
1awj3
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
oyz 1idni3h
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
8-K
crqsz02 jfn87yyvt6
3 Oct 23
Departure of Directors or Certain Officers
4:31pm
8-K
042f7oqd
14 Aug 23
Other Events
8:00am
8-K
fhpom
10 Aug 23
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
7:03am
8-K
4qgpj b21ii2wef371
25 Jul 23
Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024
7:02am
8-K
4eb6wrhu
17 Jul 23
Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer
4:08pm
8-K
baxlf6a 7fq8q6qe52
1 Jun 23
June 2023 Larimar Therapeutics Corporate Presentation
4:06pm
8-K
hkx00spm g08wlboem
15 May 23
Results of Operations and Financial Condition
7:05am
8-K
pbxz wbaw243jwy0
12 May 23
Submission of Matters to a Vote of Security Holders
4:02pm
ARS
sjofc4ogtx2g
11 Apr 23
Annual report to shareholders
4:08pm
8-K
kgmj55nvewm45
6 Apr 23
Departure of Directors or Certain Officers
4:06pm
S-8
qgv9vxct5scv6ohs
14 Mar 23
Registration of securities for employees
5:16pm
S-8
ik36o
14 Mar 23
Registration of securities for employees
5:15pm
8-K
65rteryh g77bgs3
14 Mar 23
Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results
7:32am